🇺🇸 FDA
Pipeline program

Tumor infiltrating lymphocytes (TIL) LN-145

2000025837

Phase 2 small_molecule completed

Quick answer

Tumor infiltrating lymphocytes (TIL) LN-145 for Metastatic Triple Negative Breast Cancer is a Phase 2 program (small_molecule) at IOVANCE BIOTHERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
IOVANCE BIOTHERAPEUTICS, INC.
Indication
Metastatic Triple Negative Breast Cancer
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials